Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam ATTR Drug Receives Orphan Drug Status in Europe

Premium

Alnylam Pharmaceuticals this week announced that its transthyretin-mediated amyloidosis drug ALN-TTRsc has received orphan drug status from European regulators.

ALN-TTRsc is a subcutaneously administered version of the company's ATTR drug patisiran, an intravenous therapy currently in Phase III testing in patients with a manifestation of the disease called familial amyloidotic polyneuropathy.

The subcutaneous version recently entered Phase II testing for a version of ATTR called cardiac amyloidosis. That trial is assessing the tolerability of the drug, as well as its effect on knocking down serum levels of its target protein, in 15 patients. Data from the trial is expected later this year.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.